GlassScriptPhysician profile
John W Tucker
NPI 1669453882
$4,277.17
in general payments reported to CMS, 2019-2025
29 companies · $1,052 in 2025
The $1,052 reported for 2025 was more than what 81% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $571 · 2022: $752 · 2023: $1,055 · 2024: $846 · 2025: $1,052.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,945 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,945.11 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $839.29 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $670.23 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $432.25 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $313.77 | 2021-2024 | Xarelto |
| Glaxosmithkline, LLC. | $289.93 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $229.54 | 2021-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $203.96 | 2022-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $164.58 | 2022-2025 | |
| Lilly USA, LLC | $135.13 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Novartis Pharmaceuticals Corporation | $130.54 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $113.11 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.99 | 2021-2024 | Xifaxan |
| Paratek Pharmaceuticals, INC. | $69.49 | 2023-2025 | Nuzyra, Xhance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $63.12 | 2023-2024 | Caplyta |
| Harmony Biosciences LLC | $57.94 | 2023 | Wakix |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $55.73 | 2025 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $54.50 | 2021-2023 | Yupelri |
| Sunovion Pharmaceuticals INC. | $49.47 | 2021 | |
| Pfizer INC. | $48.02 | 2024-2025 | |
| Vanda Pharmaceuticals INC. | $41.98 | 2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $40.59 | 2025 | Austedo Xr |
| Amgen INC. | $40.25 | 2024 | Prolia, Evenity |
| Corcept Therapeutics | $38.79 | 2024-2025 | Korlym |
| Ultragenyx Pharmaceutical INC. | $30.96 | 2022 | |
| Alexion Pharmaceuticals, INC. | $26.65 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.87 | 2021 | |
| Eisai INC. | $14.56 | 2021 | |
| Xeris Pharmaceuticals, INC. | $14.26 | 2025 | Gvoke Hypopen |
| Organon LLC | $11.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Tucker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.